BioCity Group

NanoSyrinx is a biotechnology company focused on developing a novel biologics drug delivery platform that targets therapeutic proteins and peptides to the cytosol of cells. Through synthetic biology, the company seeks to transport payloads directly into cell interiors, aiming to improve the efficacy, safety, and cost-effectiveness of treatments. The platform is designed to serve the biopharmaceutical sector by enabling targeted delivery of biologics to intracellular targets, with potential to enhance treatment outcomes across multiple indications.

Founded in 2018 and based in Sheffield, UK, Rinri Therapeutics is a biotechnology company dedicated to developing regenerative stem cell-based therapies for treating hearing loss. Its innovative therapy aims to replace damaged sensory cells of the inner ear, restoring patients' hearing.

Maxwellia specializes in converting prescription drugs into over-the-counter versions. Founded in 2013, it offers services such as SwitchScreen for opportunity assessment, SwitchUp for switch design and risk mitigation, and SwitchAbility for process support.

Bio-Images Drug Delivery Ltd, based in Glasgow, United Kingdom, specializes in drug formulation and delivery systems. The company offers a comprehensive range of services tailored to meet individual client needs, including troubleshooting, formulation development, and both in vitro and in vivo testing. Bio-Images is known for its patented time release technology, OralogiK, which provides precise control over drug release timing and location, allowing for the oral delivery of single, multi-dose, or combination drugs within a timeframe of one to twelve hours after ingestion. This technology supports various dosing strategies, such as nighttime administration and multi-phased delivery, which enhance therapeutic efficacy. Additionally, the company employs gamma scintigraphy to analyze the in vivo behavior of formulations, offering insights into disintegration timing, gastric emptying, and gastrointestinal transit. Bio-Images also features a clinical division that manages all aspects of clinical study processes, from protocol development and regulatory submissions to the production of compliant clinical study reports.

Kinomica is a United Kingdom based medicine research and diagnostics company that develops KScan, a phosphoproteomic diagnostic platform designed to measure intracellular kinase activity and cell signaling pathways in cells and tissues. The platform supports the selection of targeted therapies by providing direct activity measurements of multiple endogenous kinases and comprehensive signaling network coverage, enabling clinicians to tailor treatment decisions for cancer patients and other conditions. By combining proprietary bioinformatics with phosphoproteomics, Kinomica identifies biomarkers and assesses pharmacodynamic responses to inform drug targeting and biomarker strategies. The company was founded in 2016 and is based in Macclesfield, United Kingdom.

NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at the University of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham.

Kinomica is a United Kingdom based medicine research and diagnostics company that develops KScan, a phosphoproteomic diagnostic platform designed to measure intracellular kinase activity and cell signaling pathways in cells and tissues. The platform supports the selection of targeted therapies by providing direct activity measurements of multiple endogenous kinases and comprehensive signaling network coverage, enabling clinicians to tailor treatment decisions for cancer patients and other conditions. By combining proprietary bioinformatics with phosphoproteomics, Kinomica identifies biomarkers and assesses pharmacodynamic responses to inform drug targeting and biomarker strategies. The company was founded in 2016 and is based in Macclesfield, United Kingdom.

Founded in 2018 and based in Sheffield, UK, Rinri Therapeutics is a biotechnology company dedicated to developing regenerative stem cell-based therapies for treating hearing loss. Its innovative therapy aims to replace damaged sensory cells of the inner ear, restoring patients' hearing.

Genxt is a company that specializes in developing B2B solutions aimed at streamlining enterprise adoption of artificial intelligence while minimizing risks associated with private data and machine learning model disclosure. Additionally, Genxt offers a bioinformatics platform that enhances data collaboration in the field of genomics. This platform utilizes trusted execution technology to ensure secure multi-party data processing without the risk of cross-domain data disclosure. By enabling clients to work with fragmented data in a non-invasive, secure, and compliant manner, Genxt facilitates the advancement of data-driven insights in various sectors.